Efficacy of subsequent treatments in patients who progressed to mCRPC following treatment with apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): A post-hoc analysis of the SPARTAN phase III trial.

被引：0
|
作者：
Oudard, Stephane
Hadaschik, Boris A.
Antoni, Laurent
Diels, Joris
Luccarini, Irene
Thilakarathne, Pushpike
Smith, Matthew Raymond
Small, Eric Jay
机构：
[1] Univ Paris, Georges Pompidou Hosp, Paris, France
[2] Univ Duisburg Essen, Essen, Germany
[3] Janssen Pharmaceut NV, Beerse, Belgium
[4] Massachusetts Gen Hosp, Boston, MA USA
[5] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
157
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial
    Meisel, Alexander
    von Felten, Stefanie
    Vogt, Deborah R.
    Liewen, Heike
    de Wit, Ronald
    de Bono, Johann
    Sartor, Oliver
    Stenner-Liewen, Frank
    EUROPEAN JOURNAL OF CANCER, 2016, 56 : 93 - 100
  • [22] Relationship between apalutamide (APA) exposure and metastasis-free survival (MFS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN
    Smith, M. R.
    Perez-Ruixo, C.
    Ackaert, O.
    Ouellet, D.
    Chien, C.
    Uemura, H.
    Olmos, D.
    Mainwaring, P. N.
    Lee, J. Y.
    Yu, M. K.
    Perez-Ruixo, J-J.
    Small, E. J.
    ANNALS OF ONCOLOGY, 2018, 29 : 278 - 278
  • [23] Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)
    Small, E. J.
    Cella, D.
    McQuarrie, K.
    Saad, F.
    Hadaschik, B. A.
    Graff, J. N.
    Uemura, H.
    Oudard, S.
    Yu, M. K.
    Hudgens, S.
    Lopez-Gitlitz, A.
    Rooney, B.
    Morris, M.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer A Secondary Analysis of the SPARTAN Randomized Clinical Trial
    Roy, Soumyajit
    Malone, Shawn
    Wing, Kevin
    Chowdhury, Simon
    Kishan, Amar U.
    Sun, Yilun
    Wallis, Christopher J. D.
    Mohamad, Osama
    Jia, Angela Y.
    Swami, Umang
    Zaorsky, Nicholas G.
    Morgan, Scott C.
    Ong, Michael
    Agarwal, Neeraj
    Spratt, Daniel E.
    Small, Eric J.
    Saad, Fred
    JAMA NETWORK OPEN, 2024, 7 (10)
  • [25] METASTASIS-FREE SURVIVAL (MFS) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) WITH PROSTATE-SPECIFIC ANTIGEN (PSA) DECLINE TO < 0.2 NG/ML FOLLOWING APALUTAMIDE (APA) TREATMENT: POST HOC RESULTS FROM THE PHASE 3 SPARTAN STUDY
    Graff, Julie N.
    Saad, Fred
    Hadaschik, Boris A.
    Mainwaring, Paul N.
    Uemura, Hiroji
    Chowdhury, Simon
    Oudard, Stephane
    Olmos, David
    Lee, Ji Youl
    Lopez-Gitlitz, Angela
    Bhaumik, Amitabha
    Londhe, Anil
    Cheng, Shinta
    Todd, Mary B.
    Smith, Matthew R.
    Small, Eric J.
    JOURNAL OF UROLOGY, 2019, 201 (04): : E503 - E503
  • [26] Outcomes of patients (pts) with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who progressed to metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TRUMPET registry.
    Shevrin, Daniel H.
    Symanowski, James Thomas
    Shore, Neal D.
    Lin, Daniel W.
    Russell, David
    Kral, Pavol
    Song, Yi
    El-Chaar, Nader N.
    Karsh, Lawrence Ivan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC)
    Mainwaring, P.
    Small, E.
    Saad, F.
    Chowdhury, S.
    Oudard, S.
    Hadaschik, B.
    Graff, J.
    Olmos, D.
    Lee, J.
    Uemura, H.
    Lopez-Gitlitz, A.
    Espina, B.
    Shu, Y.
    Rackoff, W.
    Rooney, B.
    Londhe, A.
    Cheng, S.
    Smith, M.
    BJU INTERNATIONAL, 2019, 123 : 46 - 47
  • [28] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    CANCER RESEARCH, 2019, 79 (13)
  • [29] Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Small, Eric Jay
    Saad, Fred
    Chowdhury, Simon
    Oudard, Stephane
    Hadaschik, Boris A.
    Graff, Julie Nicole
    Olmos, David
    Mainwaring, Paul N.
    Lee, Ji Youl
    Uemura, Hiroji
    Lopez-Gitlitz, Angela
    Espina, Byron M.
    Shu, Youyi
    Rackoff, Wayne R.
    Rooney, Oliver Brendan
    Londhe, Anil
    Cheng, Shinta
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [30] Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
    Uemura, Hiroji
    Matsushima, Hisashi
    Kobayashi, Kazuki
    Mizusawa, Hiroya
    Nishimatsu, Hiroaki
    Fizazi, Karim
    Smith, Matthew
    Shore, Neal
    Tammela, Teuvo
    Tabata, Ken-ichi
    Matsubara, Nobuaki
    Iinuma, Masahiro
    Uemura, Hirotsugu
    Oya, Mototsugu
    Momma, Tetsuo
    Kawakita, Mutsushi
    Fukasawa, Satoshi
    Kobayashi, Tadahiro
    Kuss, Iris
    Le Berre, Marie-Aude
    Snapir, Amir
    Sarapohja, Toni
    Suzuki, Kazuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (03) : 578 - 590
12345